Testing JS207 for advanced lung cancer after prior treatments
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called JS207 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after standard treatments like chemotherapy and immunotherapy. It aims to see if JS207 can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called NSCLC that is advanced (stage IIIB/IIIC) or has spread to other parts of the body, and it cannot be removed by surgery.
- You have already received treatment with an immunotherapy drug (PD-1 or PD-L1 inhibitor) combined with platinum-based chemotherapy, and your cancer got worse.
- You have at least one tumor that can be measured on scans (like CT or MRI).
- Your cancer does not have a neuroendocrine component (a specific cell type).
- You do not have an EGFR mutation or ALK fusion (specific genetic changes) that would make targeted therapy an option.
- Your tumors are not wrapped around major blood vessels or have significant necrosis (dead tissue) that could cause bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new drug combination (JS207 with or without JS015) along with chemotherapy for people with advanced colorectal cancer that has not spread to other parts of the body. It aims to see if the treatment is safe and helps shrink tumors.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Advanced NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.